Saturday 17 October 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024. In the quarter to June 2026, revenue grew 18.5%, EPS grew 14.3%, free cash flow grew 74.2% and total debt rose 1.43%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
7.08
0.52
−6.84%
Follow TKNO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 5 | 5 |
+8 more TTM periods Free account |
| (24.19%) | (23.92%) | (22.83%) | (22.79%) | ||
| (16.25%) | (16.15%) | (15.52%) | (15.73%) | ||
ROIC |
(16.93%) | (16.90%) | (17.52%) | (17.68%) | |
Return on Tangible Assets |
(26.51%) | (26.29%) | (25.12%) | (25.22%) | |
Average Days of Receivables |
45.17 | 49.53 | 41.60 | 47.09 | |
Free Cash Flow per Share |
(0.14) | (0.17) | (0.18) | (0.20) | |
Free Cash Flow |
(7.35) | (9.06) | (9.79) | (10.49) | |
Capital Expenditures |
(1.08) | (1.16) | (1.15) | (1.37) | |
| Other line items | |||||
Cash ROIC |
(7.88%) | (9.45%) | (9.49%) | (9.72%) | |
Accounts Receivable Turnover |
8.29 | 7.41 | 9.08 | 8.17 | |
Accounts Payable Turnover |
21.64 | 17.39 | 24.58 | 26.69 | |
Inventory Turnover |
3.94 | 4.10 | 3.91 | 3.77 | |
Average Days of Payables |
18.36 | 21.41 | 18.57 | 14.40 | |
Days of Inventory on Hand |
88.26 | 90.96 | 95.08 | 91.85 | |
Tax Rate |
0.01 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5.10% | 5.39% | 5.42% | 5.70% | |
Selling, General and Administrative Expense of Revenue |
63.06% | 64.89% | 66.81% | 67.59% | |
Share Based Compensation of Revenue |
6.74% | 7.83% | 8.46% | 8.59% | |
Interest Coverage |
(18.14) | (20.78) | (23.91) | (28.65) | |
Operating CF/Net income |
0.37 | 0.46 | 0.50 | 0.50 | |
Depreciation/Fixed assets |
0.16 | 0.15 | 0.14 | 0.14 | |
Capex/Depreciation |
(0.18) | (0.19) | (0.19) | (0.23) | |
Revenue per Share |
0.81 | 0.78 | 0.76 | 0.74 | |
Operating CF per Share |
(0.12) | (0.15) | (0.16) | (0.17) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.03) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 |
Columns are period end dates